Vivo Therapeutics Reports Significant Improvement of Second and Third Patients Implanted with Neuro-Spinal Scaffold

Posted byclientekdevPosted instem cell research

http://www.businesswire.com/news/home/20150706005264/en/InVivo-Therapeutics-Reports-Significant-Improvement-Patients-Implanted#.VZxPMMrbKUk

CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (NVIV) today announced a one-month post-implant update for the third study patient and a six-month post-implant update for the second study patient in the company’s ongoing pilot trial of its investigational Neuro-Spinal Scaffold in patients with complete acute spinal cord injury.